Skip to main content
Premium Trial:

Request an Annual Quote

Newly Restructured Incyte Posts Flat Revenue, Widened Loss in Q4

NEW YORK, Feb. 13 - Incyte Genomics on Wednesday reported widened loss over flat revenue in the fourth quarter as it gathers momentum to become a full-fledged drug developer.

 

Incyte said that killing off its custom genomics database business caused revenue to dip to $54.8 million in the period in the current quarter compared with $55.4 million in the year-ago period.

 

R&D spending in the period ended Dec. 31 dipped accordingly, to $50.5 million from $53.3 million last year. Despite this, net loss in the quarter ballooned to $14.8 million, or $.22 per share, compared with $7.4 million, or $.11 per share year over year.

 

Incyte had approximately $508 million in cash, cash equivalents, and marketable securities as of Dec. 31.

 

The company, which recently underwent a dramatic transition from database provider to fledgling pharma hound, said it expects to generate between $130 million and $150 million in the current year.

 

It also said it plans on moving a portion of its business into "collaborative or other kinds of agreements," which it warned would reduce near-term revenue and might make quarterly revenue "irregular."

 

Incyte said it anticipates expenses from its information business to reach between $125 million and $130 million in t 2002, and that its nascent drug-discovery arm will spend between $85 million and $90 million during the year.

 

It says it is bracing for a net loss of between $65 million and $85 million this year.

 

"I want to emphasize that we are moving aggressively into the therapeutic discovery and development arena," Paul Friedman, Incyte's CEO, said in a statement. "Because we are using our information assets differently--specifically the database and our intellectual property--we will have lower near term revenues. We plan to use a portion of Incyte's database subscription and intellectual property licensing business to facilitate co-development or other types of agreements," he explained.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.